-
A worldwide observational study with 96,000 hospitalized COVID-19 patients showed that those who were treated with hydroxychloroquine or chloroquine had a higher mortality rate and a particularly increased risk of cardiac arrhythmia.
-
A study of the Augsburg University Hospital, Germany, recently showed that the lung tissue of deceased COVID-19 patients is irreversibly damaged.
-
There has not yet been any clear evidence of the brain areas involved in many executive functions involved in behavioral control. A new study has identified this crucial region, with the help of a unique patient and the dysexecutive syndrome.
-
A dominant posture could help children to feel more confident in school. This is the result of a new study that gives first hints on how pupils could feel better at school with simple exercises.
-
Researchers in Munich have shown that Ewing's sarcoma interferes with a special signaling pathway in bone development. This could open up new therapeutic options, especially for highly aggressive tumors.
-
The Frankfurt University of Applied Sciences has developed the nursing robot "ROSWITHA". Based on state-of-the-art autonomy technology, an interdisciplinary scientific team will devote the next three years to develop its robotic embodiment.
-
A retrospective observational study from the USA compared whether there are differences between a Roux-Y gastric bypass and the application of sleeve gastrectomy for remission in type-2 diabetes.
-
The knowledge of diagnostic tests to detect SARS-CoV-2 infection is still evolving. A recent article describes how to interpret the two types of diagnostic tests commonly used, the RT-PCR and IgM/IgG tests.
-
The WHO warns against the issuing of "immunity passports" that would allow people with SARS-CoV-2 antibodies to resume their activities or to travel. To date, there is no evidence that these people are immune to reinfection. The reliability of the tests is also in question.
-
A freely-downloadable document is born from the confluence of scientific literature, social issues, physicians’ experiences in clinical practice, and exchange amongst colleagues.
-
A study group compared the SARS virus and the new coronavirus responsible for COVID-19. Some differences are highlighted in the interaction of viruses with the ACE2 receptor and the enzyme TMPRSS2.
-
Dr. Isabel Muñoz was a family physician in Salamanca, Spain. Her passing at 59 years old, brings into question the protection of health professionals and of people in quarantine.
-
Michael J. Peluso, University of California, San Francisco (USA), presented at the virtual CROI in March 2020 the largest case series to date of patients who developed early HIV infection under PrEP.
-
Thanks to modern antiretroviral therapy, the life expectancy average of HIV-infected people has improved significantly. It is now only 3.3 years less than that of non-infected persons. However, many of them suffer from comorbidities.
-
HIV-infected people often suffer from sleep disorders, which in turn increases the risk of a heart attack. An analysis of CNICS patient groups showed that patients with stressful insomnia increase the risk of type 2 myocardial infarction.
-
In the ADVANCE study, treatment with dolutegravir+tenofovir alafenamide+emtricitabine was associated with a higher risk of obesity, metabolic syndrome, increase in visceral and subcutaneous fat, and long-term risk of developing diabetes.
-
Metabolic complications are a major challenge of HIV infection and antiretroviral therapy (ART). Many of these complications are mediated by adipose tissue. Current knowledge on this topic was presented at the virtual CROI 2020.
-
Long-acting antiretroviral therapeutics might be particularly suitable for patients who have problems swallowing, who fear stigmatization or who do not want to take medication every day.
-
ROADMAP study showed that a kick-and-kill strategy with the HDAC inhibitor romidepsin and the bNAb 3BNC117 proved to be ineffective in 20 patients with chronic HIV infection under long-term ART.
-
The effect of intramuscular administration of long-acting cabotegravir and rilpivirine is not inferior to monthly injections in maintenance therapy for patients with HIV infection, as found by the ATLAS-2M study.
